Maxim initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target The Antibody-Drug Conjugate space is high value at both the commercial and M&A levels, including numerous partnering and licensing deals for preclinical and discovery stage ADC assets, the analyst tells investors in a research note. Combined with challenging biotech markets and broad market headwinds, this story is under-the-radar and just getting started, Maxim argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics initiated with a Buy at Maxim
- Akari Therapeutics Shareholders Approve Key AGM Resolutions
- Akari Therapeutics releases ‘What This Means’ segment for investors
- Akari Therapeutics announces granting of patent protection in India
- Akari Therapeutics price target raised to $7 from $4 at Alliance Global